No wearing-off effect of erenumab or fremanezumab for chronic migraine prevention: a single-center, real-world, observational study.
Cephalalgia
; 44(1): 3331024231222915, 2024 Jan.
Article
in En
| MEDLINE
| ID: mdl-38215232
ABSTRACT
BACKGROUND:
The present study investigates the wearing-off effect in adults with chronic migraine treated with erenumab or fremanezumab.METHODS:
This real-world observational study was based on pre-collected headache diaries from chronic migraine patients in treatment with either monthly injections of 140 mg of erenumab or 225 mg of fremanezumab. Consistent wearing-off was defined as an increase of ≥2 weekly migraine days in the last week compared to the second week over two consecutive 4-week treatment periods. The primary endpoint was wearing-off in the total population. The secondary endpoints were difference in wearing-off in (i) a subgroup of patients treated with erenumab and fremanezumab and (ii) consistent wearing-off in patients with a ≥30% reduction in monthly migraine days, compared to baseline, in the two consecutive treatment months.RESULTS:
In total, 100 patients (erenumab n = 60, fremanezumab n = 40) were included. Sixty-two out of 100 (62%) patients had consistent ≥30% treatment response on antibody therapy in both months (erenumab n = 36, fremanezumab n = 26). There was no consistent wearing-off over the two consecutive months from week 2 to week 4 (3.04%, p = 0.558). There was no wearing-off within the erenumab (p = 0.194) or the fremanezumab (p = 0.581) groups. Among the ≥30% treatment responders, there was no consistent wearing-off over the two consecutive months (2.6%, p = 0.573).CONCLUSIONS:
There was no wearing-off in treatment responders, which is in alignment with premarketing data from placebo-controlled phase III studies. These data suggest that patients should be informed upfront that no wearing-off effect is expected because anxiety for attacks at the end of the month per se may generate migraine attacks.Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Antibodies, Monoclonal, Humanized
/
Migraine Disorders
/
Antibodies, Monoclonal
Type of study:
Clinical_trials
/
Observational_studies
Limits:
Adult
/
Humans
Language:
En
Journal:
Cephalalgia
Year:
2024
Document type:
Article
Country of publication:
Reino Unido